Beigene Drug Patent Portfolio

Beigene owns 1 orange book drug protected by 12 US patents Given below is the list of Beigene's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11786531 Methods of treating B-cell proliferative disorder 19 Jan, 2043
Active
US11896596 Methods of treating B-cell proliferative disorder 19 Jan, 2043
Active
US11911386 Methods of treating B-cell proliferative disorder 19 Jan, 2043
Active
US11701357 Treatment of B cell cancers using a combination comprising Btk inhibitors 24 Jun, 2039
Active
US10927117 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
Active
US11591340 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
Active
US11851437 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
Active
US11884674 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
Active
US11970500 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
Active
US10570139 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators 22 Apr, 2034
Active
US11142528 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators 22 Apr, 2034
Active
US9447106 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators 22 Apr, 2034
Active


Given below is the list of recent legal activities going on the following drug patents of Beigene.

Activity Date Patent Number
Patent litigations
Mail Patent eCofC Notification 14 May, 2024 US11786531
Recordation of Patent eCertificate of Correction 14 May, 2024 US11786531
Patent eCofC Notification 14 May, 2024 US11786531
Email Notification 14 May, 2024 US11786531
Mail Certificate of Correction Memo 04 Apr, 2024 US11786531
Certificate of Correction Memo 03 Apr, 2024 US11786531
Post Issue Communication - Certificate of Correction 03 Apr, 2024 US11786531
Payment of Maintenance Fee, 8th Year, Large Entity 19 Mar, 2024 US9447106
Recordation of Patent Grant Mailed 27 Feb, 2024 US11911386
Email Notification 27 Feb, 2024 US11911386
Patent eGrant Notification 27 Feb, 2024 US11911386
Mail Patent eGrant Notification 27 Feb, 2024 US11911386
Patent Issue Date Used in PTA Calculation 27 Feb, 2024 US11911386
Recordation of Patent eGrant 27 Feb, 2024 US11911386
Recordation of Patent eGrant 13 Feb, 2024 US11896596


Beigene's Family Patents

Beigene drugs have patent protection in a total of 28 countries. It's US patent count contributes only to 23.0% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Beigene Drug List

Given below is the complete list of Beigene's drugs and the patents protecting them.


1. Brukinsa

Brukinsa is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11786531 Methods of treating B-cell proliferative disorder 19 Jan, 2043
(18 years from now)
Active
US11896596 Methods of treating B-cell proliferative disorder 19 Jan, 2043
(18 years from now)
Active
US11911386 Methods of treating B-cell proliferative disorder 19 Jan, 2043
(18 years from now)
Active
US11701357 Treatment of B cell cancers using a combination comprising Btk inhibitors 24 Jun, 2039
(14 years from now)
Active
US10927117 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
(12 years from now)
Active
US11591340 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
(12 years from now)
Active
US11851437 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
(12 years from now)
Active
US11884674 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
(12 years from now)
Active
US11970500 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof 15 Aug, 2037
(12 years from now)
Active
US10570139 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators 22 Apr, 2034
(9 years from now)
Active
US11142528 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators 22 Apr, 2034
(9 years from now)
Active
US9447106 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators 22 Apr, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brukinsa's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Beigene News

BeiGene's therapy for esophageal cancer approved by US FDA, according to Yahoo News Canada

17 Mar, 2024

BeiGene's treatment for esophageal cancer receives approval from US FDA - report from Yahoo Finance

14 Mar, 2024

The esophageal cancer therapy developed by BeiGene receives approval from the US FDA

14 Mar, 2024

Multiple pharmaceutical companies including BeiGene, BMS, and AZ-FibroGen featured in Fierce Pharma Asia news.

01 Mar, 2024

See More